Table 2. Hazard ratios (HRs) and 95% confidential intervals (CIs) for recurrence free survival (RFS).

	Univariate analysis		Multivariate analysis
	HRs (95% CI)	P value	HRs (95% CI)	P value
Age		<0.001		<0.001
>35	1		1
≤35	0.355(0.227–0.555)		0.416(0.256–0.674)
T stage		0.001		0.514
1	1		1
2	1.5661.005–2.442)	0.048	1.293(0.801–2.085)	0.293
3	4.196(2.162–8.142)	<0.001	1.740(0.833–3.635)	0.141
N stage		<0.001		<0.001
0	1		1
1	1.694(1.066–2.690)	0.026	1.339(0.809–2.214)	0.256
2	3.702(2.111–6.492)	<0.001	2.938(1.601–5.393)	0.001
3	5.313(3.057–9.232)	<0.001	3.969(2.068–7.619)	<0.001
LVI		<0.001		0.272
Negative	1		1
Positive	2.377(1.468–3.848)		1.349(0.791–2.300)
HG		0.990
I and II	1
III	1.001(0.825–1.216)
A20		<0.001		<0.001
Low	1		1
High	2.672(1.710–4.175)		2.324(1.446–3.736)
ER		0.535
Negative	1
Positive	1.127(0.772–1.646)
PR		0.535
Negative	1
Positive	0.887(0.607–1.296)
HER2		0.862
Negative	1
Positive	0.954(0.560–1.624)
TNBC vs non-TNBC		0.842
non-TNBC	1
TNBC	1.042(0.692–1.570)

LVI, Lymphovascular invasion; HG, histologic grade; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; TNBC, triple negative breast cancer